

Gdańsk, 9 June 2026

## INFORMATION ON THE OPENING AND SELECTION OF THE OFFER

The Contracting Authority – the Polish Lymphoma Research Group (PLRG) hereby informs that by 9 June 2026, two (2) offers were submitted in response to the procedure concerning the provision of services consisting in making available a platform for the central review of PET/CT scans and performing imaging study interpretations for the non-commercial clinical trial: “Efficacy and Tolerability of N-AVD compared to BrECADD in patients with advanced Hodgkin Lymphoma (N-BRAVE)”, Protocol No. PLRG-HL05, EU CT No. 2026-525263-41-00, financed from the state budget under funding granted by the Medical Research Agency (Agencja Badań Medycznych).

The following offers were received:

1. Pixilib SAS, 2 rue Léonce Castelbou, 31000 Toulouse, France, VAT No. FR65904494689, Registration Number (France): RCS Toulouse 904494689.
2. DIXIT Solutions, Alexandru Stancu, Via Agostino da Montefeltro 2, 10134 Torino, Italy, VAT No. IT10493140015.

**Following the market analysis and evaluation of the submitted offers in accordance with the requirements set out in Request for Quotation No. 04/2026, the offer submitted by Pixilib SAS was considered the most advantageous.**

The offer is not subject to rejection, as it meets all requirements specified by the Contracting Authority and achieved the highest score according to the evaluation criteria adopted in the procurement procedure.

Consequently, a contract will be concluded with the above-mentioned Contractor.

.....  
President Polish Lymphoma Research Group  
Prof. Jan Maciej Zaucha, MD, PhD